Theravance Biopharma Inc (0TB) - Total Liabilities

Latest as of September 2025: €182.78 Million EUR ≈ $213.69 Million USD

Based on the latest financial reports, Theravance Biopharma Inc (0TB) has total liabilities worth €182.78 Million EUR (≈ $213.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Theravance Biopharma Inc cash conversion from operations to assess how effectively this company generates cash.

Theravance Biopharma Inc - Total Liabilities Trend (2014–2024)

This chart illustrates how Theravance Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Theravance Biopharma Inc to evaluate the company's liquid asset resilience ratio.

Theravance Biopharma Inc Competitors by Total Liabilities

The table below lists competitors of Theravance Biopharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Camden National Corporation NASDAQ:CAC	USA	$6.28 Billion
Metals Acquisition Limited NYSE:MTAL	USA	$870.02 Million
Diagnósticos da América S.A SA:DASA3	Brazil	R$13.26 Billion
BlackRock Technology and Private Equity Term Trust NYSE:BTX	USA	$23.50 Million
Standard Foods Corp TW:1227	Taiwan	NT$9.26 Billion
Heritage Commerce Corp NASDAQ:HTBK	USA	$5.06 Billion
Vamos Locação de Caminhões Máquinas e Equipamentos S.A SA:VAMO3	Brazil	R$19.84 Billion
Shandong Weida Machinery Co Ltd SHE:002026	China	CN¥931.92 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Theravance Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 0TB stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.48	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.79	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.44	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Theravance Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Theravance Biopharma Inc (2014–2024)

The table below shows the annual total liabilities of Theravance Biopharma Inc from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	€178.62 Million ≈ $208.82 Million	+5.69%
2023-12-31	€169.00 Million ≈ $197.58 Million	+2.06%
2022-12-31	€165.60 Million ≈ $193.60 Million	-76.79%
2021-12-31	€713.39 Million ≈ $834.03 Million	-7.69%
2020-12-31	€772.81 Million ≈ $903.49 Million	+22.15%
2019-12-31	€632.67 Million ≈ $739.65 Million	+3.41%
2018-12-31	€611.82 Million ≈ $715.29 Million	+87.55%
2017-12-31	€326.22 Million ≈ $381.39 Million	+12.87%
2016-12-31	€289.02 Million ≈ $337.90 Million	+406.60%
2015-12-31	€57.05 Million ≈ $66.70 Million	+18.90%
2014-12-31	€47.98 Million ≈ $56.10 Million	--

About Theravance Biopharma Inc

F:0TB Germany Biotechnology

Market Cap

$835.30 Million

€714.48 Million EUR

Market Cap Rank

#9975 Global

#1192 in Germany

Share Price

€14.10

Change (1 day)

-0.70%

52-Week Range

€7.45 - €17.50

All Time High

€38.30